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Abstract
Introduction: Although smokers with severe mental illnesses (SSMI) make quit attempts at comparable
levels to other smokers, fewer are successful in achieving smoking cessation. Specialized smoking cessation
treatments targeting their needs can be effective but have not been widely disseminated. Telephone delivered
interventions, including by quitlines, show promise. However, few SSMI contact quitlines and few are referred
to them by health professionals. Mental health peer workers can potentially play an important role in
supporting smoking cessation. This study will apply a pragmatic model using peer workers to engage SSMI
with a customized quitline service, forming the "Quitlink" intervention.
Methods: A multi-center prospective, cluster-randomized, open, blinded endpoint (PROBE) trial. Over 3
years, 382 smokers will be recruited from mental health services in Victoria, Australia. Following completion
of baseline assessment, a brief intervention will be delivered by a peer worker. Participants will then be
randomly allocated either to no further intervention, or to be referred and contacted by the Victorian Quitline
and offered a targeted 8-week cognitive behavioral intervention along with nicotine replacement therapy
(NRT). Follow-up measures will be administered at 2-, 5-, and 8-months post-baseline. The primary outcome
is 6 months continuous abstinence from end of treatment with biochemical verification. Secondary outcomes
include 7-day point prevalence abstinence from smoking, increased quit attempts, and reductions in cigarettes
per day, cravings and withdrawal, mental health symptoms, and other substance use, and improvements in
quality of life. We will use a generalized linear mixed model (linear regression for continuous outcomes and
logistic regression for dichotomous outcomes) to handle clustering and the repeated measures at baseline, 2-,
5-, and 8-months; individuals will be modeled as random effects, cluster as a random effect, and group
assignment as a fixed effect.
Discussion: This is the first rigorously designed RCT to evaluate a specialized quitline intervention
accompanied by NRT among SSMI. The study will apply a pragmatic model to link SSMI to the Quitline,
using peer workers, with the potential for wide dissemination.
Clinical Trial Registration: Trial Registry: The trial is registered with ANZCTR (www.anzctr.org.au):
ACTRN12619000244101 prior to the accrual of the first participant and updated regularly as per registry
guidelines. Trial Sponsor: University of Newcastle, NSW, Australia.
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Błażej Misiak,
Wroclaw Medical University, Poland
Reviewed by:
Alain Dervaux,
University Hospital Center (CHU) of
Amiens, France
Kazutaka Ohi,
Kanazawa Medical University, Japan
*Correspondence:
Amanda L. Baker
amanda.baker@newcastle.edu.au
Specialty section:
This article was submitted to
Schizophrenia,
a section of the journal
Frontiers in Psychiatry
Received: 30 August 2018
Accepted: 19 February 2019
Published: 19 March 2019
Citation:
Baker AL, Borland R, Bonevski B,
Segan C, Turner A, Brophy L,
McCarter K, Kelly PJ, Williams JM,
Baird D, Attia J, Sweeney R,
White SL, Filia S and Castle D (2019)
“Quitlink”—A Randomized Controlled
Trial of Peer Worker Facilitated Quitline
Support for Smokers Receiving Mental
Health Services: Study Protocol.
Front. Psychiatry 10:124.
doi: 10.3389/fpsyt.2019.00124
“Quitlink”—A Randomized Controlled
Trial of Peer Worker Facilitated
Quitline Support for Smokers
Receiving Mental Health Services:
Study Protocol
Amanda L. Baker 1*, Ron Borland 2,3, Billie Bonevski 1, Catherine Segan 2,3, Alyna Turner 1,4,5,
Lisa Brophy 3,6,7, Kristen McCarter 1, Peter J. Kelly 8, Jill M. Williams 9, Donita Baird 1,
John Attia 1, Rohan Sweeney 10, Sarah L. White 2, Sacha Filia 2 and David Castle 5,11
1 Faculty of Health and Medicine, University of Newcastle, Newcastle, NSW, Australia, 2Cancer Council Victoria, Melbourne,
VIC, Australia, 3Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia,
4 IMPACT Strategic Research Centre, School of Medicine, Barwon Health, Deakin University, Geelong, VIC, Australia,
5Department of Psychiatry, University of Melbourne, Melbourne, VIC, Australia, 6Mind Australia Limited, Melbourne, VIC,
Australia, 7 School of Allied Health, Human Services and Sport, La Trobe University Melbourne, Melbourne, VIC, Australia,
8 Illawarra Health and Medical Research Institute and the School of Psychology, University of Wollongong, Wollongong, NSW,
Australia, 9Division of Addiction Psychiatry, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ,
United States, 10Centre for Health Economics, Monash University, Melbourne, VIC, Australia, 11Department of Psychiatry, St
Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia
Introduction: Although smokers with severe mental illnesses (SSMI) make quit attempts
at comparable levels to other smokers, fewer are successful in achieving smoking
cessation. Specialized smoking cessation treatments targeting their needs can be
effective but have not been widely disseminated. Telephone delivered interventions,
including by quitlines, show promise. However, few SSMI contact quitlines and few are
referred to them by health professionals. Mental health peer workers can potentially play
an important role in supporting smoking cessation. This study will apply a pragmatic
model using peer workers to engage SSMI with a customized quitline service, forming
the “Quitlink” intervention.
Methods: A multi-center prospective, cluster-randomized, open, blinded endpoint
(PROBE) trial. Over 3 years, 382 smokers will be recruited from mental health services
in Victoria, Australia. Following completion of baseline assessment, a brief intervention
will be delivered by a peer worker. Participants will then be randomly allocated either
to no further intervention, or to be referred and contacted by the Victorian Quitline
and offered a targeted 8-week cognitive behavioral intervention along with nicotine
replacement therapy (NRT). Follow-up measures will be administered at 2-, 5-, and
8-months post-baseline. The primary outcome is 6 months continuous abstinence
from end of treatment with biochemical verification. Secondary outcomes include 7-day
point prevalence abstinence from smoking, increased quit attempts, and reductions
in cigarettes per day, cravings and withdrawal, mental health symptoms, and other
substance use, and improvements in quality of life. We will use a generalized linear mixed
model (linear regression for continuous outcomes and logistic regression for dichotomous
outcomes) to handle clustering and the repeated measures at baseline, 2-, 5-, and
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8-months; individuals will be modeled as random effects, cluster as a random effect, and
group assignment as a fixed effect.
Discussion: This is the first rigorously designed RCT to evaluate a specialized quitline
intervention accompanied by NRT among SSMI. The study will apply a pragmatic model
to link SSMI to the Quitline, using peer workers, with the potential for wide dissemination.
Clinical Trial Registration:
Trial Registry: The trial is registered with ANZCTR (www.anzctr.org.au):
ACTRN12619000244101 prior to the accrual of the first participant and updated
regularly as per registry guidelines.
Trial Sponsor: University of Newcastle, NSW, Australia.
Keywords: smoking, smoking cessation, quitline, peer worker, mental illness, severe mental illness, psychosis,
depression
INTRODUCTION
Smokers living with severe mental illness (SSMI) die around
two decades earlier than the general population, due largely to
smoking-related diseases (1). Survey data from the United States
(2, 3), United Kingdom (4), and Australia (5) consistently
highlight that smoking is not declining at the same rate among
SSMI as among the general population. In Australia, smoking
rates in 2010 for people with psychotic illness were 67 vs. 65% in
1997/98 (5). Rates of smoking increase with severity of themental
illness. The Australian National Drug Strategy Household Survey
(6) showed that in 2016, among those diagnosed with a mental
illness in the previous 12 months, daily smoking rates were
highest among people with a psychotic disorder (schizophrenia
49.3%, bipolar 37.3%, other psychotic disorder 32.2%), followed
by anxiety disorders (28.5%), depression (27.3%), and eating
disorders (24%). In comparison, 12% of people from the
general population in Australia smoke daily (7). Economic
costs associated with smoking in people with mental illness are
significant and include costs of treatment of tobacco-related
diseases, work-related absenteeism, and premature mortality.
In the UK, in the 2009/2010 financial year, the estimated
economic cost of smoking in people with mental disorders was
at £2.3 billion (8).
There is a vicious cycle between smoking and poorer mental
and physical health. In addition to increased mortality, SSMI
have more psychiatric symptoms, increased hospitalizations, and
the requirement for higher doses of some psychiatric medications
(9). This is because components of tobacco smoke accelerate their
metabolism (10). Smoking cessation benefits mental health as
well as physical health. A recent meta-analysis of primarily non-
controlled trials found that quitting smoking is associated with
significantly improved quality of life and reduced depression,
mixed anxiety/depression, and improved positive affect. Effect
sizes for these differences were as large in people with SMI (0.40,
−0.39, −0.21, 0.68, respectively) as in the general population
(0.15, −0.30, −0.32, 0.16). The effect sizes were equal to or
larger than those of people receiving anti-depressant treatment
for mild to severe depression (range: −0.17 to −0.11) and
generalized anxiety disorder (range: −0.23 to −0.50) (11). In
addition, the recent Evaluating Adverse Events in a Global
Smoking Cessation Study (EAGLES) randomized controlled
trial (RCT) found no significant difference in the occurrence
of adverse events between the smoking cessation medications,
varenicline, bupropion, nicotine replacement therapy (NRT),
or placebo (12) among people with or without psychiatric
disorders. Further, sustained reductions in smoking have
important financial benefits and may increase the chance of
future cessation (13).
SSMI are about as likely to want to quit as those in the
general population (14), and some are able to quit (9). However,
they often require additional assistance, and overall have lower
rates of success with cessation. This can potentially be reduced
or eliminated by the delivery of additional assistance targeted
to their specific needs. SSMI are not uniformly being provided
with the additional smoking cessation assistance they need. The
problem is often overlooked by health care providers, being seen
as either too hard or a low priority (15, 16), while SSMI report
a lack of encouragement to quit (16). Mental health staff have
reported that they lack knowledge about tobacco dependence
and smoking’s relationship with mental illness (17). In addition,
existing evidence-based interventions for this population are
rare, mainly face-to-face and intensive, so without substantial
additional resources, they cannot feasibly be taken up by mental
health services.
Telephone smoking cessation support tailored for SSMI may
improve access and enhance cessation (18). Quitline smoking
cessation counseling is effective in the general population (19). A
2013 Cochrane review found that proactive telephone counseling
(where the counselor initiates one or more calls to provide
support) is more effective, with better outcomes than a single-
session reactive support call or brief interventions (19). Quitlines
offer enormous potential for SSMI. As an existing service that
can be accessed from the community, quitlines can offer an
intervention for SSMI that does not require a significant increase
in resources.
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We are aware of three RCTs that have evaluated the
effectiveness of quitline interventions among SSMI. In an under-
powered pilot randomized trial (N = 123) among a community
mental health sample, Morris et al. (20) reported that five quitline
sessions plus NRT were equivalent to a much more intensive
intervention consisting of five quitline sessions plus NRT and
also 10 group face-to-face sessions. A breath carbon monoxide
(CO) verified point prevalence abstinence rate of 10% overall
was achieved at 6 months. In a second RCT, Van der Meer
and colleagues compared a standard quitline service to standard
quitline service plus a mood management component for callers
with past major depression (N = 485) (21). Participants in both
conditions were advised to use pharmacological aids for cessation
if they smoked more than 10 cigarettes per day. Cessation
rates were higher for the treatment group who received the
additional mood module (31 vs. 22% at 6 months and 24 vs.
14% at 12 months), but biochemical verification was available
only for a small sub-sample. In the third RCT, Rogers et al. (22)
compared standard quitline counseling with specialized quitline
counseling developed for smokers attending Veterans Health
Administration mental health facilities (N = 577), referred via
electronic medical record consult. Participants in the specialized
counseling condition were significantly more likely to report 30-
day abstinence compared to the standard quitline (26 vs. 18%)
at 6 months. Together, these three RCTs suggest that telephone
interventions accompanied by smoking cessation medication
among SSMI are likely to be effective and that tailoring the
intervention specifically for mental health symptomatology is
likely to enhance results. We are aware of no adequately powered
RCT evaluating a tailored quitline intervention (addressing
mood and other symptomatology) accompanied by NRT, for
people drawn from mental health services, with biochemical
verification of self-reported abstinence. The present study aims
to address this gap.
In Australia, the Victorian Quitline has been building
counselor skills in order to support SSMI better. Segan
et al. found that a specialized quitline intervention for
smoking cessation among people with depression was workable,
valued by smokers, and increased the probability of quit
attempts (23). They then integrated key elements of our
mainly telephone delivered smoking cessation intervention,
demonstrated to be as effective as a more intensive face-to-face
delivered intervention, among people with psychotic disorders
(24, 25). The revised tailored Victorian Quitline intervention
includes structured monitoring of mental health symptoms,
nicotine withdrawal symptoms, and medication side-effects (26).
These procedures help to distinguish temporary withdrawal
symptoms from psychiatric symptoms and facilitate targeted
treatment. Feedback indicated that the structured monitoring,
combined with Quitline’s established focus on the relationship
between smoking and mood control, had a high level of
acceptance by both Quitline counselors and clients and led
to better integration of quitting with management of ongoing
mental health conditions (26). The resulting tailored smoking
cessation intervention, when coupled with peer referral, is
called Quitlink, and if shown to be effective, is likely to be
widely adopted.
Despite promising work in providing a more appropriate,
supportive, and engaging service, quitlines remain underutilized
in part because health professionals lack awareness of their
free callback service and its expertise in helping SSMI (27).
Mental health peer workers can potentially play an important
role in supporting smoking cessation. Peer workers have been
a mental health consumer or carer and this lived experience
along with their training allows them to be highly credible
sources of support for SSMI (28). Peer support, which is one
element of peer work, is based on the belief that people who
have faced, endured, and overcome adversity can offer useful
support, encouragement, hope, and mentorship to others facing
similar situations (29). As part of the recovery-oriented practice
framework (encompassing principles of self-determination and
personalized care (30), people with their own lived experience
of mental ill-health and recovery (i.e., peer workers) are viewed
as highly valuable members of the mental health workforce
(31). The peer workforce is the most rapidly growing workforce
in the Australian mental health sector, with existing research
examining peer workers finding they are effective (32). Peer
workers are strong role models, and are particularly successful
in developing hope, promoting self-esteem, and empowering
consumers (32). These unique skills are likely to be extremely
valuable in helping to promote engagement of SSMI with
quitline services (29).
Communication between quitline and the mental health
service will be a key component of this link. The mental health
service provider (utilizing peer workers) will identify smokers
who may benefit from intervention and peer workers will make
the referral to the Victorian Quitline for proactive telephone
counseling (accompanied by free NRT). With the permission
of the participant, quitline counselors will keep peer workers
and other mental health professionals updated as to quitline
participation. This project will examine program and cost-
effectiveness of “Quitlink” for people with SMI compared with
standard smoking care.
An important component of the present research is a
nested qualitative study exploring experiences of peer workers,
mental health staff, and participants (from both intervention
and control arms), including those participants who do
and do not stop smoking and/or engage with the quitline
service. We will also explore in detail the barriers to
cessation people face and the impact of smoking culture,
support people (carers/family/partners) and other factors on
intervention uptake, ongoing participation, and outcome.
Future dissemination, ongoing development of resources, and
improvement of our intervention will be informed by an
enhanced understanding of the mechanisms by which the
intervention is effective as well as refining who is likely to be
successful, and why.
AIMS
The primary aim of this research is to test the effectiveness of the
Quitlink intervention for smoking cessation among SSMI. It is
hypothesized that the intervention will be associated with higher
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rates of continued abstinence from smoking following the end of
the treatment period, relative to the control condition. Secondary
aims are to examine: (i) the cost-effectiveness of Quitlink
compared to the control condition; (ii) barriers and enablers to
making and sustaining quit attempts using qualitativemethods so
as to better understand why cessation rates among SSMI remain
low; and (iii) the effect of Quitlink on 7-day point prevalence
abstinence at 8-months, and effects on reported cigarette
consumption, rates of quit attempts, nicotine withdrawal,
expenditure on cigarettes, smoking cessationmotivation and self-
efficacy, mental health, quality of life and alcohol, and cannabis
use. We will also assess process measures such as extent of use
of advice and use of quit smoking medications (regardless of
condition). The cost-effectiveness protocol is described elsewhere
by Sweeney et al. (in submission) and the nested qualitative study
and outcome measures are described below.
METHODS
Design
A multi-center prospective, cluster-randomized, open, blinded
endpoint (PROBE) design will be employed to compare
standard smoking care alone against Quitlink. See Figure 1 for
an overview.
Rationale for Study Design
Due to the nature of the intervention under investigation (i.e.,
linking smokers to existing smoking cessation care options
readily available in the community, quitline, and NRT) there is
a high risk of contamination among residential services where
participants are living under the same roof and hence may
compare treatment received. Therefore, we will use a partial
clustering design where cluster randomization will be used
in situations where risk of contamination is particularly high
(e.g., in residential services). Individual randomization will be
used in settings where participants are approached individually
(e.g., clinics). Conceptually, this can be considered as a cluster
RCT where some clusters only contribute a single person (see
statistical methods section). This is sometimes called a split-plot
design (33).
Setting
Participants will be recruited across participating community
mental health services in Victoria, Australia, including St
Vincent’s Mental Health, and non-government organizations
such as Mind Australia Limited. Residential and non-residential
community services will be included in the study. These services
are widely distributed across the state and we will recruit from
an as yet unknown subset of sites. The majority of people
accessing these services will have been diagnosed with severe
mental illnesses such as schizophrenia, schizoaffective disorder,
bipolar disorder, delusional disorder, and depressive disorders.
Eligibility Criteria
Participant inclusion criteria are: aged at least 18 years; residing
in Victoria; smoking at least 10 cigarettes per day; and accessing
treatment or support from participating mental health agencies.
Exclusion criteria are: current engagement in Victorian Quitline’s
callback service; no ready access to a telephone; inability to
complete informed consent and/or the screening survey; acute
suicidality; myocardial infarction or unstable arrhythmia or
angina within the previous 2 weeks (NRT contraindications);
and pregnancy (as smokers who are pregnant already receive a
different extended Quitline callback service).
Around three-quarters of individuals accessing mental health
services own mobile phones (34). Landlines will be used
where people do not own mobile phones, as in our previous
studies (25, 35).
Quitline counselors: Experienced quitline counselors who
have been provided with specialist training on counseling
people with mental health issues, and who have demonstrated
competence in this work have been allocated to the study (one
dedicated counselor per caller for all calls, or to co-ordinate with
a substitute where they may be unavailable for some calls).
Standard Smoking Care
An active control condition, involving brief advice on the
importance of quitting and provision of printed information on
where to access assistance, is being utilized in this study as it
reflects what is expected of mental health services as part of
routine care (even though it is not routinely delivered).
The brief intervention provided to all participants includes
advice to quit, encouragement to use NRT, and a Quit Victoria
pack of written materials to motivate a quit attempt (e.g., costs
of smoking and benefits of quitting) and resources to support
self-management (e.g., Quitline phone number, “4Ds” strategy:
‘Delay, Deep-breathe, Drink water, Do something else’ to manage
cravings; using NRT products).
With consent, a letter will be sent by the research
team to nominated health professionals general practitioner
(GP)/psychiatrist with information about their client’s trial
participation and a link to Australia’s smoking cessation
guidelines for health professionals, which includes a list of
medications affected by smoking. No further intervention will be
provided as part of the project for those in the control condition.
Quitlink Intervention
The Quitlink intervention consists of all of the above plus:
• Referral to Quitline: immediately following the brief
intervention, the peer worker will make a proactive referral
to Quitline.
• Manual guided Quitline counseling: Quitline will then call
the participant to offer the Quitlink service. This service
includes up to seven scheduled calls with additional calls
allowed to deal with relapse crises within an 8-week period.
It includes structured monitoring of mental health symptoms,
nicotine withdrawal symptoms, and medication side-effects;
and a focus on psychoeducation including the relationship
between smoking and mood; goal setting; identification of
triggers to smoke; and facilitating problem solving and skills
building, including the use of mood management strategies
that also act to aid cessation (e.g., exercise, scheduling pleasant
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FIGURE 1 | Quitlink study design.
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activities). A dedicated Quitline counselor will manage the
quitting process for each participant.
• As in the control condition, with consent, a letter will be
sent to the person’s GP and/or psychiatrist. Additionally for
the intervention condition, peer reviewed articles that provide
practical advice to assist doctors in helping people with mental
illness to quit smoking will be included (36, 37). Additionally,
participants will receive a Quit Victoria brochure for carers
and a Quitting Mood and Experiences Diary.
• Quitline engagement with mental health services: Quitline
will provide written feedback to treatment providers at the
end of the telephone counseling program. Providers will be
encouraged tomonitor and support cessation efforts whenever
appropriate. In addition, Quitline will contact the mental
health treatment provider, if concerns arise about mental
health issues.
• NRT: Participants will initially be provided with a 4 week
supply of patches (one 21mg patch/day) plus their choice of an
oral-form NRT (gum, lozenge, inhalator, spray). The research
team will post NRT to participants with an information
pack that includes printed instructions on how to use NRT
correctly, for how long, potential side effects (and when to
notify a health care provider), and safe storage and handling.
Quitline counselors will monitor and encourage correct use
of NRT and address barriers to use. Intervention participants
that decide to use the supplied NRT will receive a final 4-week
supply of NRT as per the initial supply. Quitline counselors
will ask participant preferences for oral dose forms during the
Week 2 call (for those participants that do not engage with
Quitline, the peer worker will attempt to contact participants
to determine participant preferences for NRT) in order for
NRT to be delivered to the participant by Week 4. Participants
who desire to shift to use of a prescription-based stop smoking
medication (e.g., varenicline) will be supported to do so, but
the study will not fund the purchase (which is low for those
with health care cards as it is heavily government subsidized).
The Quitlink intervention is similar to the Quitline’s routine care
for clients disclosingmental health issues. Components unique to
this trial include the peer worker referring toQuitline, a dedicated
Quitline counselor for each participant and provision of NRT.
Discontinuation of the Quitlink Intervention
This may occur if there are alterations in the participant’s
condition which justifies the discontinuation of treatment in
the investigator’s opinion. All intervention components are
voluntary and non-essential to participation. The participant
may refuse to engage, miss scheduled telephone sessions, or
discontinue with the Quitlink intervention without affecting
study participation.
NRT use is also optional (recommended, but not expected),
and use or non-use will not affect whether they can participate in
Quitline counseling or follow-up interviews.
Intervention Training and Supervision
Quitline counseling delivery will be provided by existing Quitline
Victoria counselors, holding at least a Certificate III level
qualification in counseling and trained in the World Health
Organization Smoking Cessation approach (38) by a Quit
psychologist. In addition, all are experienced in conducting
smoking interventions among SSMI and in 2014 received a 1-day
face to face training workshop led by experienced investigators
focusing on the provision of structured monitoring of mood,
nicotine withdrawal, and psychiatric medication side-effects. It is
standard practice for the Quitline counselors to receive monthly
group supervision led by a qualified counselor and monthly
individual supervision which entails a psychologist reviewing
notes and listening to two calls (<10 and >20min) to facilitate
reflective practice and quality assurance. Counselors will also
receive a minimum of 1 day of additional training focused on
refreshing these skills and processes contained in the Quitlink
treatment manual. The Quitlink treatment manual developed for
this study will be used to ensure that all participants receive a
minimum standard of behavioral counseling, are supported to
use NRT therapy provided and that communication with mental
health services occurs as necessary.
Peer workers will identify as being or having been a mental
health consumer and preferably will also be ex-smokers or non-
smokers who have experience working with SSMI and are aware
of the challenges involved in smoking cessation for this group.
Peer workers will receive training and ongoing supervision
from investigators experienced in working with peer workers
(including investigators with lived experience). Training and
supervision will cover recruitment issues, delivery of standard
care (brief intervention), baseline assessment, the automated
randomization procedure, how to refer to Quitline, fidelity,
distress management procedures, and suicide risk assessment
and referral.
Intervention Fidelity
For purposes of the present study, a random selection of 20%
of Quitlink intervention participants will be made, and routinely
recorded calls will be rated for fidelity to the treatment manual by
an independent rater using a checklist derived from the treatment
manual which includes core behavior change techniques (BCTs)
relevant to smoking cessation. BCTs are defined as the smallest
identifiable components of an intervention that in themselves
have the potential to change behavior (39).
Concurrent Treatment
In both the Standard Smoking Care and Quitlink Intervention
conditions, participants will be able to partake of any
interventions initiated by themselves or their health providers
during the course of the study and these will be monitored at the
follow-up assessments.
Outcome Measures
Outcome measures will be assessed at 2-, 5-, and 8-months post
baseline, by telephone. These will be conducted by independent
assessors who will remain blind to intervention allocation.
Outcome measures will all be assessed before any process
measures where answers could suggest experimental condition.
All assessment instruments are widely used in mental health
and/or tobacco treatment research and practice (see Table 1)
and cover the domains hypothesized to be impacted upon by
the intervention.
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TABLE 1 | Assessment schedule.
Assessments Baseline 2 month 5 month 8 month
Demographic characteristics X
MENTAL ILLNESS DIAGNOSIS
Self-report
- Have you ever received a mental health diagnosis?
- Have you ever been diagnosed with a psychotic disorder?
X
MINI (diagnostic interview) X * *
McLean screening instrument for borderline personality
disorder
X * *
MEDICATIONS
Current medications X/E
Medication side effects X
SMOKING MEASURES:
Current smoking and quit attempts X X X X
7 day point prevalence abstinence (self-reported) X X X
6 month prolonged abstinence (primary outcome) X
CO Monitoring (those reporting abstinence) A
Heaviness of Smoking Index X S S S
Tobacco types X
Cost X S S S
History (age first smoked) X
Social influences X
Cravings X X X X
Smoking use motives X
Situations not allowed to smoke X X X
Goal X
Motivation to quit X S S S
Confidence to quit X
Self-efficacy X X X
Products/services to help quit (including NRT, Quitline) X X X X
Nicotine replacement products (helpfulness, likely use) X
Counseling preference (in person or telephone) X
Minnesota Nicotine Withdrawal Scale (only two items in follow
ups)
X X X X
MENTAL HEALTH:
Kessler-10 X X X X
SUBSTANCE USE:
Alcohol (AUDIT-C) X X X X
Cannabis use with tobacco question X X X X
Cannabis (First question of CUDIT-R) X X X X
QUALITY OF LIFE:
AQoL-8D X X X X
MEDICATIONS—NRT/CESSATION:
Process measure (i.e., provided to intervention participants) E
Perceived support—GP, Psychiatrist, other health
professional
X
QUITLINE USE:
Number, length, content and timing of calls E
SERVICE USE
Hospitalizations and other intensive health service use X X
Time off from work and usual duties X X X
Financial stress questions X X X X
Therapeutic Alliance: X
WAIT-3 X$
Peer worker brief intervention question X
Qualitative interviews I I I
PBS/MBS cost data E
AUDIT-C, Alcohol Use Disorders Identification Test – Brief (40); AQoL-8D, Assessment of Quality of Life-8D (41); CUDIT-R, Cannabis Use Disorders Identification Test – Revised (42); CO,
Carbon monoxide; GP, General Practitioner; Kessler-10, Kessler Psychological Distress Scale (43); MINI, Mini International Neuropsychiatric Interview (44); NRT, Nicotine Replacement
Therapy; WAIT-3, Working Alliance Inventory for Tobacco-−3 (45); MBS, Medicare Benefits Schedule; PBS, Pharmaceutical Benefits Scheme.
Key
*If not captured at previous assessment.
E Extracted data.
S Current smokers.
$If used Quitline.
A Those reporting abstinence.
I Selected subsample.
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Primary Outcome
The primary outcome is defined as continued abstinence from
smoking since the end of the treatment period, i.e., 6 months
sustained abstinence, with no relapse (defined as 7+ days of
continuous smoking, and no reported smoking in the last week),
with biochemical verification at 8-month follow-up. Sustained
abstinence will be assessed via the following question: “When
did you last smoke a cigarette, even a puff?” If a participant
reports prolonged abstinence at the 8 month follow up, and no
smoking in the last week, they will be asked to attend a face to
face visit to complete CO testing for objective validation using a
Micro+ Smokelyzer, with a reading of 8 ppm or higher defined
as indicative of recent smoking.
Secondary Outcomes
Smoking
Secondary outcomes assessed at 2-, 5-, and 8-months post
baseline will include:
7-day point prevalence abstinence, based on “Have you smoked
at least part of a cigarette in the last 7 days?”
Reported cigarettes smoked per day (for daily smokers) or
cigarettes per week (for non-daily smokers).
Expenditure on cigarettes.
Number of quit attempts of 24 h or more, 1 week or more, and 1
month or more in the previous 3 months or since last assessed.
Time to relapse: in those who do relapse will be determined by
asking when they first smoked after a quit attempt.
Number of subsequent quit attempts among those who relapsed.
Hospitalizations and other intensive health service use.
Financial stress questions adapted from Siahpush and
Carlin (46).
Productivity impacts (time off work or other duties).
Heaviness of Smoking Index (HSI): Nicotine dependence is
assessed using this two item Index (47, 48). It uses a six-point
scale calculated from the number of cigarettes smoked per day
(1–10, 11–20, 21–30, 31+) and the time to first cigarette after
waking (≤5, 6–30, 31–60, and 61+ min). Nicotine dependence
is then categorized into a three-category variable: low (0–1),
medium (2–4), and high (5–6). The HSI has been found to have
good reliability and reasonable predictive validity (49).
Cravings: assessed by one item taken from the International
Tobacco Control (ITC) Four Country Survey (50, 51),
“Currently, how often do you get strong cravings to smoke
tobacco?” with the response options of: (1) Hourly or more
often; (2) Several times per day; (3) At least once a day; and (4)
Less than daily. Difficulty in coping with situations in which
smoking is not allowed is also assessed, on a 4-point Likert Scale
from “very,” “moderately,” “mildly” to “not at all difficult.”
Withdrawal symptoms: as assessed by the Minnesota Nicotine
Withdrawal Scale [MNWS; (52)], an eight item ordinal scale
rating withdrawal symptoms from 0 (not present) to 3 (severe).
At baseline the MNWS is administered, with two symptoms
(concentration and appetite) assessed at follow-up. The MNWS
has been shown to have good reliability and predictive
validity (53).
Mental health
Kessler Psychological Distress Scale [Kessler-10; (43)] a 10-item
scale of non-specific psychological distress. Low scores (10–15)
indicate little or no psychological distress and higher scores
indicate increasing levels of distress (moderate, 16–21; high, 22–
29; and very high, 30–50). It has shown consistent psychometric
properties across major sociodemographic subsamples (54).
Substance use
The Alcohol Use Disorders Identification Test—Brief [AUDIT-
C; (40)] a three item screening tool used to identify hazardous
alcohol use or active alcohol use disorders. It is scored on a scale
of 0–12 with a cut off of 3 (women) or 4 (men). For men, it has
been shown to have a sensitivity of 0.90 and specificity of 0.45; for
women the sensitivity is 0.80, and specificity is 0.87.
The Cannabis Use Disorders Identification Test—Revised
[CUDIT-R; (42)] is a briefer (8-item) and more refined version
of the CUDIT (55), a simple modification of the AUDIT.
Items cover the domains of consumption, cannabis problems,
dependence, and psychological features. The CUDIT-R was
found to comprise a single factor, with high test-retest reliability
(r = 0.871), high internal consistency (α = 0.914), and
discriminant validity (area under the curve = 0.960). Only
question 1, “How often do you use cannabis? (over the last 2
months)” is included in the present study (never, monthly or less,
2 to 4 times a month, 2 to 3 times a week, 4 or more times a
week). In addition, participants who use cannabis are asked “Do
you ever mix tobacco with your cannabis?” with response options
of “Yes, always or nearly always,” “Yes, sometimes” or “No, never
or very rarely.”
Quality of life
The Assessment of Quality of Life 8 Dimension [AQoL-8D;
(41)] instrument is comprised of 35 items from which eight
dimensions (independent living, pain, senses, mental health,
happiness, coping, relationships, and self-worth) and two “super-
dimensions” (physical and psychosocial) are derived. It has
demonstrated strong content validity and has been found to
perform relatively well in populations with SMI (56). The 35
items may be reduced to a single utility score. Use of the
instrument enables calculation of quality adjusted life years
(QALYs) experienced across the two study arms, which will be
reported in the cost-effectiveness analysis.
Covariate or process measures
Demographic variables (e.g., gender and age).
History of tobacco smoking and quitting.
Types of tobacco used.
Social influences on smoking, e.g., lives with other smokers.
Smoking Use Motives: As part of this trial self-reported
reasons for smoking are assessed using a modified version of
the Drinking Motives Questionnaire (57), with additional items
developed by Spencer et al. (58) to explore the use of substances
to alleviate psychotic symptoms (positive and negative).
At baseline, participants will be asked whether they have a
preference for in person or telephone counseling. They will also
be asked to rate the likely helpfulness of NRT to long term
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quitting (not at all, some, moderately, extremely) and likelihood
of use in the longer term (not at all, some,moderately, extremely).
Motivation to quit: assessed by a single question adapted from
Crittenden et al. (59), “Howmuch do you want to quit smoking?”
(not at all, a little, some, very much). At follow-up assessments,
“Are you trying to quit smoking altogether or are you planning
to keep smoking at this level?”
Confidence to quit (at baseline) is measured by the following
question: “How confident are you that you can stop smoking
for good in the next 2 months if you wanted to?” (not at all,
somewhat, moderately, very, extremely).
Self-efficacy in quitting is measured by the following question
adapted from Perkins et al. (60): “How confident are you that
you will not smoke at all tomorrow?” (not at all, somewhat,
moderately, very, extremely). For those who quit at follow-up,
“How confident are you that you will be able to stay quit long-
term and become a permanent ex-smoker?” (not at all, somewhat,
moderately, very, extremely).
Medications: Changes in use of prescribed psychotropic
medication.
Medication side effects: At baseline, participants will be asked
to rate 10 symptoms during the past week (e.g., dry mouth,
increased thirst) on an ordinal scale from 0 (not present) to
3 (severe). This measure is informed by the most common
adverse side effects of psychiatric medications as identified in
the Side Effect Survey, which has demonstrated validity and
reliability (61).
Treatment received (use of NRT and Quitline—number and
length of calls).
Objective data on service use (number and length of calls) will
be extracted from the Quitline database for all participants (as
some control participants may have self-referred).
Therapeutic alliance with Quitline counselor: the three-item
Working Alliance Inventory for Tobacco (45), measuring goal,
task, and bond on a five item Likert Scale (seldom, sometimes,
fairly often, very often, always) will be administered at the 2-
month follow-up. The three-item measure has been found to
have acceptable-good internal consistency and construct validity.
Self-reported service use and satisfaction: participants’ use
and assessment of level of support they have received for
quitting from their mental health service, doctors, and other
health professionals.
Linked data on service and prescription medication use
from the Australian Government subsidized Medicare and
Pharmaceutical Benefits Schemes.
Safety data
Adverse events will be collected at all follow-up time points, with
prompting via questions asking how the participant has been
feeling in general and if they have any health concerns.
Sample Size Determination
Based on our previous study (23) which achieved a 15%
prolonged abstinence rate in depressed smokers, and knowing
rates are considerably less among those with more severe mental
illnesses (62) we anticipate that for the primary outcome of
prolonged abstinence at 8 months, prolonged abstinence will
occur in 1% of the control arm vs. 8% in the intervention arm.
To detect this effect with 80% power at p = 0.05, we require 134
per arm. We expect ∼30% attrition, inflating the sample size to
191/arm or 382 overall. Thus, we will recruit 382 smokers over
36 months and follow up at 2-, 5-, and 8-months post-baseline,
completing the study over a 4.5-year period.
Participant Recruitment and Retention
Peer workers will visit sites and provide information to both
staff and potential participants about the study to encourage
recruitment. Service staff will be asked to refer potential
participants (at any stage of their treatment) to the study via
the peer worker. Additional recruitment strategies will be by
advertising (e.g., flyers, newsletters, online via service websites)
and peer workers attending community meetings and other
events to inform potential participants directly about the study
to encourage self-referral.
For those whomeet eligibility criteria and decide to participate
in the study, the peer worker will gain written informed consent
from the participant. Provision is made on the consent form for
opting in or out of possible participation in a qualitative study
of experiences of trying to stop smoking and for participation in
further studies.
Telephone follow-up and compensation for completed
assessments will aid in increasing retention rates. Monthly check-
in texts (to remind participants to inform the researchers if
their contact details change) will be conducted to help maintain
contact with participants, and 3 monthly follow-up will assist
with accurate participant recall of smoking and quitting history.
Participants will receive a $40 gift card for baseline and for each
completed follow-up assessment and a $40 gift card for the 8-
month face-to-face assessment for biochemical verification of
self-reported smoking cessation (if required).
Upon completion of the baseline assessment, the peer worker
will provide standard smoking care (described above) to all
participants. The peer worker will then access the randomization
allocation for the participant via the eCRF program, and
communicate appropriately with the participant.
Randomization
Following completion of the baseline assessment, a brief
intervention will be delivered by a peer worker—prior
to randomization—to ensure all participants receive the
recommended minimum standard care, in a manner that is
unbiased by the outcome of randomization. Following this,
the computer program used to complete the baseline will
randomize to condition using 1:1 randomization. Participants
will be randomly allocated to either no further intervention, or
to be contacted by Quitline who will offer a targeted callback
counseling intervention with NRT provided, over an 8-week
period. As stated above, cluster randomization will be used
in situations where risk of contamination is higher, such as
residential services, stratified by short- or long-term residence,
with 1:1 allocation. Individual randomization will be used in
services where contamination of risk is lower, via permutated
block sizes of 4 and 6 to avoid incomplete blocks, stratified for
site. Participants will be allocated a unique computer-generated
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study number. Randomization will be independently managed
by the trial epidemiologist (JA) and uploaded to a web-based
data capture tool (Research Electronic Data Capture; REDCap)
that will also have case report forms (eCRF) created for the
project using REDCap.
Following randomization, those in the intervention group
will be told of the additional supports they will be getting
(see above). Controls will be simply told the session is over
and reminded of when the first follow-up survey might
be expected.
Blinding
Outcome assessors will be blinded to study design and allocation
and will have training and regular supervision on practices to
maintain blinding in a PROBE design study. These have been
previously used successfully by our team (63). Importantly,
outcomes assessors will ask participants about smoking outcomes
prior to any questions about use of cessation supports,
questions that often produce answers which can indicate likely
experimental condition.
The mental health practitioners, follow-up assessors,
qualitative interviewers, and Quitline counselors are located in
separate organizations, which will maximize maintenance of the
outcomes assessors’ blindness to study design and treatment
allocation. Outcomes assessors will access only contact details,
and not treatment files. The eCRF permissions will not allow
outcomes assessors to access information about the participant’s
treatment allocation.
Participants will be aware of what support they are receiving,
but not of the comparison condition due to the “limited
disclosure” approach. Participants will be informed about what
is involved (i.e., the follow-up assessments) and that they may
be offered support with smoking cessation. They will not be
informed of the specifics of the support (i.e., intervention will
receive proactive referral to Quitline and be supplied with
NRT). Control participants will be informed of the options
available and encouraged to follow up on any they are interested
in, in the usual manner (GP/other health professional/self-
referral to Quitline). The outcomes assessment team will remain
blinded to treatment allocation until completion of the study.
Data analysts will be blinded by labeling the intervention
conditions “A” and “B.”
Unblinding
Following baseline assessment and delivery of the brief
intervention, peer workers, the trial coordinator, quitline
counselors, qualitative staff, and associated investigators will be
unblinded to treatment allocation.
Stepwise Procedures
This protocol is presented in accordance with the 2013 SPIRIT
(Standard Protocol Items: Recommendations for Interventional
Trials) Statement (see Supplementary Material). The schedule
of enrolment, interventions, and assessments is summarized
in Table 2.
Data Management
All data will be entered electronically via eCRF using (REDCap)
tools (64) hosted at Hunter New England Local Health District
on a secure server. Redcap is a secure, web-based application
designed to support data capture for research studies providing
an intuitive interface for data entry, audit trails for tracking
data manipulation and export, automated export procedures for
downloads to statistical packages and procedures for importing
data from external sources. The lead investigator (and/or
delegate) and study coordinators will conduct ongoing data
checking and cleaning.
Participants’ personal details will be accessed, used, and stored
according to relevant legislations. Access to external health data
(e.g., Quitline, MBS/PBS, health records) will only occur with
the consent of the participant in accordance with protocols
of relevant external agencies (e.g., Commonwealth Department
of Human Services for MBS/PBS data). The trial conduct and
safety data will be monitored by a Data Safety Monitoring
Board (DSMB).
Statistical Methods
Primary and Secondary Outcomes
Independent and blinded statisticians from the CReDITSS
Unit at the Hunter Medical Research Institute, Australia,
supervised by AI Attia, will conduct analyses of the primary and
secondary outcomes.
Analyses will be carried out using a cluster randomized trial
framework where the individuals (n= 150) are treated as clusters
that contribute only one person, the short-term residential
programs are clusters that contribute an average of 15 people
each (10 programs × 15 people/program = 150 total) and the
long-term programs are clusters that contribute 10 people each (6
programs× 10 people/program= 60). We will use a generalized
linear mixed model (linear regression for continuous outcomes
and logistic regression for dichotomous outcomes) to handle the
clustering and the repeated measures at baseline, 2-, 5-, and 8-
months; individuals will be modeled as random effects, cluster
as a random effect, and group assignment as a fixed effect.
Mixed models allow for missing data for the primary intention
to treat analysis, but a sensitivity analysis using a worst case
scenario (baseline value for continuous outcomes or relapse for
dichotomous outcomes in case of missing value) will also be
carried out.
Intervention participants who do not complete the
intervention, and participants who miss an assessment follow-
up time point, will be kept in the study and contacted for
later assessments (unless they choose to withdraw from the
follow-up assessments).
Exploratory Analyses
We plan to examine whether the amount of intervention
(Quitline counseling, NRT) received by participants is related to
outcomes.We will also explore different imputation strategies for
missing data related to outcomes.
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TABLE 2 | Stepwise procedures.
Contact/visit Intervention period Follow-up period
Week −1 0 1 2 3 4 5 6 7 8 9 10 … 21 22 … 34 35
Visit number 1 2 3 4
ENROLLMENT
Screening (inclusion/exclusion) X X
Informed consent X X
BASELINE ASSESSMENT X
Standard smoking care X
Randomization X
INTERVENTION*
Referral to Quitline X
Contacted by Quitline and
smoking cessation initiated
X
Quitline determines preferred oral
NRT for second 4-week supply
X
NRT dispensing X X
Smoking cessation program X X X X X X X X
FOLLOW-UP ASSESSMENTS X X X
Blinded follow up assessment
conducted (all participants)
X X X
Potential qualitative interviewees
identified**
X X X
Qualitative interviews
conducted**
X X X
CO monitoring (on reported
abstainers)
X
ADVERSE EVENTS
Unprompted (serious/severe) X X X X X X X X
Prompted (all) X X X
*Intervention group only. **Participants will be purposely selected at each of the assessment timepoints (2, 5, and 8 months) to be invited for interview.
Economic Evaluation
A cost-effectiveness analysis of Quitlink will be conducted
alongside the trial described here, using data 8 months post
randomization. A modeled analysis will estimate future costs and
benefits of smoking cessation beyond the trial period, over the life
course. Full protocol details of this are presented in this Special
Issue in Sweeney et al. (in submission). In brief, incremental cost-
effectiveness ratios (ICER) will be calculated for the cost ($AUD)
per successful quit and quality adjusted life year (QALY) gained
(i.e., cost-utility) as a result of Quitlink when compared with
usual care. Healthcare system and limited societal perspectives
will be taken.
Qualitative Evaluation
A nested qualitative study will be conducted. All interviews
(participants and workers) will be audio recorded, transcribed,
and a general inductive approach will be taken to the
analysis (65).
Participant Interviews
Semi-structured individual in-depth interviews will be conducted
with 72 participants. The (unblinded) qualitative researchers
will access assessment data (REDCap) to view participants’
cigarette consumption and service use data. They will use
these data to purposively invite participants at each of the
assessment timepoints (2-, 5-, and 8-months) for interview.
Potential participants will be sent a flyer via text, mail, or
email (depending on contact information available) asking
them to participate in an interview. Upon affirmation, they
will be provided the full Information Statement on the
interview component.
Participant Selection
At 2months, 30 participants will be interviewed (15 in each study
arm, with cessation outcomes balanced across groups to negate
any potential therapeutic effect of the additional qualitative
interviews). The majority of the interviews (∼10 per arm) will
be with participants who have either not reduced smoking levels
or have made only some reduction in smoking (<50%). Having
a mix of those who have engaged with the intervention (attended
4+ Quitline sessions; or engaged in other treatments) and those
who have not engaged or under-engaged (1–3 sessions) will
enable identification of both barriers to engagement and barriers
to change.
At 5 months, another 30 participants will be interviewed
(15 per treatment arm, balanced for smoking outcomes). The
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majority (∼10 per arm) will be “relapsers” (defined as those
who have reduced consumption by 50–100% at 2 months but
have resumed or increased use by 5 months), to allow a focus
on medium term barriers to cessation maintenance, again with
a mix of those who are engaged and those who are non-
or under-engaged.
At 8 months, 12 participants will be interviewed (no
balancing required as this is after primary endpoint collection),
including ∼6 who have relapsed (in order to focus on longer
term barriers to cessation maintenance). At each time point,
interviews will also be conducted with people who have
successfully quit and maintained cessation to determine whether
those who are successful face the same barriers as others
but overcome them, and/or use the intervention in different
ways. Participants in the qualitative study will be remunerated
$40 for participation in individual interviews expected to
take∼45 min.
Mental Health and Quitline Victoria
Counselor Interviews
Interviews will evaluate the acceptability of the intervention
among mental health practitioners (including peer workers)
and Quitline counselors. Semi-structured individual in-
depth interviews will be conducted with 15 mental
health practitioners to enable data collection to reach
saturation and for key themes to be identified (66).
For Quitline counselors, three group interviews (4–
5 counselors per group) will be conducted. Interviews
with mental health practitioners and Quitline counselors
will explore their experience of the program and
its strengths and weaknesses from their perspective.
Mental health practitioners will also be asked to
focus on the implementation and sustainability of the
Quitlink intervention.
Data Safety Monitoring Board
A Data Safety Monitoring Board (DSMB) will be established.
The DSMB will monitor safety and adverse events reported and
will convene as required throughout the duration of the trial.
The DSMB will be composed of individuals with appropriate
expertise (e.g., clinical trials, statistical expertise, mental health
expertise) who are independent from the study and free of
conflict of interest, and where this is not practical, measures
will be taken to minimize the perceived conflict of interest.
The DSMB will have the capacity to contribute to decisions
regarding continuation or discontinuation of the trial based on
scientific and ethical factors. The DSMB will operate under the
rules of an approved charter that will be written and reviewed
by the DSMB. Each data element that the DSMB needs to
assess will be clearly defined in the DSMB charter. The DSMB
will provide its input to the Chief Investigator, and this will
be reported to HRECs and other regulatory bodies as per
local guidelines.
Safety Monitoring
Adverse events (AEs) will be collected and reported as per
Good Clinical Practice guidelines, from the point of enrolment
until end of their participation. Follow-up assessors will prompt
for all AEs as part of the interview schedule, while Quitline
counselors will record any serious or severe events (SAEs)
reported during counseling, as per current Quitline protocols,
and will report these to research staff. If a participant withdraws
from the study with an ongoing AE during the treatment
phase, AEs will be followed up until it is resolved; or 7 days
following withdrawal, at which time participants will be advised
to contact their treating physician if AEs persist. The DSMB
will review safety data on a regular basis, with SAEs and other
significant safety issues reported immediately to the DSMB and
further (e.g., governing ethics committee/s) as necessary as per
local guidelines.
ANTICIPATED RESULTS
This RCT will test the effectiveness of the Quitlink intervention
for smoking cessation among SSMI. We anticipate that the
intervention will be associated with significantly higher rates
of continued abstinence from smoking at 8-month follow-
up, relative to the control condition. We also anticipate the
intervention will be more cost-effective compared to the
control condition of usual care and reduced financial stress
for participants. Using qualitative methods, we will also
identify barriers and enablers to making and sustaining quit
attempts. A range of secondary outcomes will be measured
on follow-up occasions and we expect that the Quitlink
intervention will be associated with significantly better
outcomes on these variables (higher rates of 7-day point
prevalence abstinence, quit attempts, smoking cessation
motivation and self-efficacy, mental health, and quality of
life and lower reported cigarette consumption, nicotine
withdrawal symptoms, expenditure on cigarettes, and alcohol,
and cannabis use).
ETHICS AND DISSEMINATION
Prior to participation in the trial, the person will be fully
informed about the research and given ample time and
opportunity to enquire about details and decide whether or
not to participate. If they agree to participate they will be
asked to sign the study specific consent form. To ensure
anonymity and to limit disclosure, participants will be assigned
a unique identifier at the time of randomization. Results
arising from the RCT will be published in peer-reviewed
journals and disseminated at international conferences. Results
will be reported in such a way that participants will not
be identifiable.
Research Ethics Approval
Ethics approval has been obtained through St Vincent’s Hospital,
Melbourne (HREC Reference Number: HREC/18/SVHM/154),
the University of Newcastle HREC (HREC Reference Number:
H-2018-0192) and the Cancer Council Victoria, HREC (HREC
Reference Number: 1807).
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Protocol Amendments
Each study site will only be able to start data collection once
the relevant Ethics Committee approval is obtained. In the
case of proposed protocol changes, an amendment will be
submitted to the Ethics Committees for approval, and the trial
coordinating center will ensure all study staff are provided
with new documentation. Any significant protocol changes
will be updated on the ANZCTR and reported in the final
outcomes paper.
Consent or Assent
The study is based on the principles of Good Clinical Practice
according to the Declaration of Helsinki. Potential participants
will be given oral and written explanation of the study including
the potential risks, their right to withdraw at any time and
the details of data protection and confidentiality and sufficient
time to ask questions. A signed consent form will be obtained.
Participants will be given the opportunity to agree or decline
to being contacted for ancillary studies, without effecting
participation in the main trial. A copy of the PICF will be given
to the person.
Confidentiality
The trial will be conducted in accordance with applicable Privacy
Acts and Regulations. All information regarding trial participants
will be treated in strict confidence. Participants’ identifying
details will be stored separately from other data. Participants will
be informed of the potential reasons for breaching confidentiality
in the PICF (risk of harm to self or others). Data, which
identify any trial participant, will not be revealed to anyone
not directly involved in the trial or the clinical care of
that participant.
Access to Data
All data will be considered the property of the trial chairperson,
who, in consultation with the trial management committee, will
be responsible for presentations and publications arising from
this trial.
Dissemination Policy
Trial findings will be summarized and posted to participants who
have indicated they would like a copy of the results.
DISCUSSION
The Quitlink study is the first rigorously designed RCT
to evaluate a specialized quitline intervention accompanied
by NRT, for people with SMI, with biochemical verification
of self-reported abstinence. Accessible smoking interventions
like quitlines are clearly required to improve the mental
and physical health of smokers in receipt of mental health
treatment and links with mental health services are crucial
to ensure maximum utilization. A major strength of this
study is that it is demonstrably an intervention that can and
will be used if the trial demonstrates it helps: it uses two
strategies that are currently funded, i.e., quitline and peer
workers, but not currently co-ordinated. Quitlines exist but are
underutilized by those with SMI; likewise, peer workers are
employed but do not uniformly see smoking cessation as part
of their role. The study investigates a model for how these
two existing strategies can be co-ordinated to maximize the
health impact for SSMI, who often wish to quit but are not
properly supported to do so. Having peer workers trained in
assessment, brief smoking cessation advice, and proactive referral
to quitline is more likely to attract SSMI to consider smoking
cessation. It is a simple and potentially cost effective method of
increasing access to smoking cessation services in the mental
health sector.
Limitations
There are three main limitations associated with this trial.
Firstly, due to cluster randomization of residential sites, the
peer workers will become aware of each site’s allocation.
Peer workers will be carefully trained and supervised not to
communicate this information. They will also be supervised
so as to encourage equal recruitment across control and
intervention sites. Secondly, outcome to 8-months has been
chosen as the focus of this study so as to examine medium
term smoking, which parallels that for well populations (67).
However, it would be informative to follow the sample
over a longer timeframe to measure longer-term health and
other benefits.
Conclusions
If Quitlink is shown to be effective, it has the potential to
greatly improve individuals’ longevity, quality of life, mental
health, and reduce health care costs. This is an innovative
and practical service delivery model that has the potential
to ensure that smokers with SMI have access to best-
practice smoking cessation treatment. Secondly, regardless
of effectiveness outcomes, the project’s qualitative study will
provide greater insights into the barriers faced by smokers
with SMI and will assist in the development of even more
effective interventions.
The intervention can be quickly and directly translated
to quitlines and mental health services, to improve rates
of smoking cessation among SSMI. Study findings will
be of significant interest to consumer and carer groups,
the broader community sector, as well as researchers
and clinicians. The rigorous study design, inclusion of
cost-effectiveness evaluation and qualitative study are
key strengths.
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